Skip to content Skip to navigation

Stanford develops an experimental two-in-one shot that might give diabetics better control over blood sugar levels

a digital illustration of a syringe with red liquid in it
Image credit: iStock photo
May 11 2020
Fellow, Research, Stanford, Students

A Stanford research team has developed a way to boost the effectiveness of the insulin injections people with diabetes routinely take to control their blood sugar.

Led by materials scientist Eric Appel, the advance might enable patients with diabetes to take a double-acting shot that contains insulin in combination with a drug based on a second hormone, known as amylin. Amylin plays a synergistic role with insulin to control blood sugar levels after eating in a way that is more effective than insulin alone and mimics what occurs naturally with a meal.

The research team includes: Lyndsay Stapleton, a 2015 EDGE-STEM Fellow and a 2018 BIO-X Stanford Interdisciplinary Graduate Fellow; Joseph Man, a 2019-20 and 2018-19 SPICE funding recipient; Abigail Grosskopf, a 2017 Stanford Graduate Fellow; Celine Liong, a 2014 EDGE-STEM Fellow; and Catherine Meis, a 2017 Stanford Graduate Fellow.